Trial Profile
Phase 3, Randomized, 28 Days, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Brilaroxazine (RP5063) in Subjects with an Acute Exacerbation of Schizophrenia, Followed by a 52-Week Open-label Extension
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 25 Mar 2024
Price :
$35
*
At a glance
- Drugs Brilaroxazine (Primary)
- Indications Schizophrenia
- Focus Registrational; Therapeutic Use
- Acronyms RECOVER
- Sponsors Reviva Pharmaceuticals
- 13 Feb 2024 Planned End Date changed from 20 Dec 2023 to 31 Oct 2024.
- 13 Feb 2024 Planned primary completion date changed from 20 Dec 2023 to 31 Oct 2024.
- 06 Feb 2024 According to a Reviva Pharmaceuticals media release, today announced that it will host a key opinion leader (KOL) event on Thurs, Feb 15, 2024 at 12:00 PM ET. The event will focus on reviewing Reviva's positive topline results and successful completion of pivotal Phase 3 RECOVER trial and ongoing enrollment in one-year open label extension (OLE) trial.